Mehabe score: 6 G Factor: 4 Piotski Score: 6 The stock has a rating HOLD. The mehabe team score is reflective of its fundamental and technical merits. A rating above 8 is considered good buy. The stock has a G-Factor of 4 and Piotski score of 6.
Description
Anuh Pharma is engaged in the business of Manufacture of pharmaceuticals, medicinal chemical and botanical products.Site:506260Main Symbol:ANUHPHR
Stock trades at 138.0, above its 50dma 136.81. It also trades above its 200dma 131.22. The stock remains bullish on techicals
The 52 week high is at 218.70 and the 52week low is at 90.00
Price Chart
P/E Chart
Sales and Margin
Strengths
– has reduced debt.
– is almost debt free.
– is expected to give good quarter
– has been maintaining a healthy dividend payout of 34.69%
Weakness
– Stock is trading at 3.62 times its book value
– has a low return on equity of 11.62% for last 3 years.
Competition
– The industry trades at a mean P/E of 23.1x. Sequent Scien. trades at the industry’s max P/E of 72.03x. 506260 trades at a P/E of 30.6x
– Industry’s mean G-Factor is 4.0 while the mean Piotski score is 8.0. 506260 has a G-Factor of 4 and Piotski scoreof 6.
– Average 1 month return for industry is 9.1%. The max 1- month return was given by Gland Pharma: a return of 27.36 %
Quarterly Results
Sales for period ended Mar 2021 is Rs 97.15 cr compared to Rs 72.05 cr for period ended Mar 2020, a rise of 34.8%
Operating Profits reported at Rs 4.06 cr for period ended Mar 2021 vis-vis 1.89 for period ended Mar 2020 .
Operating Margins expanded 155.6 bps for period ended Mar 2021 vis-vis Mar 2020 .
The EPS for Mar 2021 was Rs 0.18 compared to Rs 0.83 for previous quarter ended Dec 2020 and Rs -0.18 for Mar 2020
Profit & Loss Statement
Profit&Loss Comments
Company reported sales of Rs 432.0 cr for period ended Mar 2021 vis-vis sales of Rs 307.0 cr for the period ended Mar 2020, a healthy growth of 28.9%. The 3 year sales cagr stood at 22.0%.
Operating margins expanded to 10.0% for period ended Mar 2021 vis-vis 8.0% for period ended Mar 2020, expansion of 200.0 bps.
Net Profit reported at Rs 28.0 cr for period ended Mar 2021 vis-vis sales of Rs 14.0 cr for the period ended Mar 2020, rising 50.0%.
Company recorded a healthy Net Profit CAGR of 18.1% over the last 3 years
Balance Sheet Statement
Cash Flow Statement
Cash Flow comments
Sales Growth
Profit Growth Statement
Profit Growth Statement
Stock Price CAGR
Return of Equity
General Comments
– The company has had stable/constant Return on Equity (RoE) metric. The RoE on Last Year basis was 13.0% compared to 12.0% over the last 3 Years. – The stock has given a return of 30% on a 1 Year basis vis-vis a return of 26% over the last 3 Years. – The compounded sales growth on a TTM bassis is 41% vis-vis a compounded sales growth of 22% over the last 3 Years. – The compounded profit growth on a TTM basis is 70% vis-vis a compounded profit growth of 18% over the last 3 Years.
Ratios
Shareholding Pattern
– Public shareholding has remained largely constant. The Jun 2021 public holding stood at 29.57% vis-vis 29.53% for Mar 2021
Conclusion
– has reduced debt.
– is almost debt free.
– is expected to give good quarter
– has been maintaining a healthy dividend payout of 34.69% – Stock is trading at 3.62 times its book value
– has a low return on equity of 11.62% for last 3 years.
The business fundamentals of the stock remain stable. Stronger near term results will build interest in the stock. We suggest to wait for a upturn in business performance.
Technically, the stock remains above its 50 DMA 136.81 and is trading at 138.0, thus bullish price action wise.
